Table 3 Expression of metabolism-related proteins in the tumor cell compartment of breast cancer metastasis according to metastatic site
From: Site-specific metabolic phenotypes in metastatic breast cancer
Parameters | Total N = 162 (%) | Bone metastasis n = 47 (%) | Brain metastasis n = 39 (%) | Liver metastasis n = 24 (%) | Lung metastasis n = 52 (%) | p-value |
|---|---|---|---|---|---|---|
Glut-1 | Â | Â | Â | Â | Â | <0.001 |
  Negative | 83 (51.2) | 35 (74.5) | 10 (25.6) | 18 (75.0) | 20 (38.5) |  |
  Positive | 79 (48.8) | 12 (25.5) | 29 (74.4) | 6 (25.0) | 32 (61.5) |  |
Hexokinase II | Â | Â | Â | Â | Â | 0.001 |
  Negative | 113 (69.8) | 41 (87.2) | 25 (64.1) | 20 (83.3) | 27 (51.9) |  |
  Positive | 49 (30.2) | 6 (12.8) | 14 (35.9) | 4 (16.7) | 25 (48.1) |  |
CAIX | Â | Â | Â | Â | Â | 0.009 |
  Negative | 130 (80.2) | 44 (93.6) | 26 (66.7) | 21 (87.5) | 39 (75.0) |  |
  Positive | 32 (19.8) | 3 (6.4) | 13 (33.3) | 3 (12.5) | 13 (25.0) |  |
MCT4 | Â | Â | Â | Â | Â | <0.001 |
  Negative | 66 (40.7) | 25 (53.2) | 4 (10.3) | 13 (54.2) | 24 (46.2) |  |
  Positive | 96 (59.3) | 22 (46.8) | 35 (89.7) | 11 (45.8) | 28 (53.8) |  |
GLS1 | Â | Â | Â | Â | Â | 0.473 |
  Negative | 83 (51.2) | 28 (59.6) | 17 (43.6) | 11 (45.8) | 27 (51.9) |  |
  Positive | 79 (48.8) | 19 (40.4) | 22 (56.4) | 13 (54.2) | 25 (48.1) |  |
GDH | Â | Â | Â | Â | Â | 0.610 |
  Negative | 2 (1.2) | 1 (2.1) | 1 (2.6) | 0 (0.0) | 0 (0.0) |  |
  Positive | 160 (98.8) | 46 (97.9) | 38 (97.4) | 24 (100.0) | 52 (100.0) |  |
ASCT2 | Â | Â | Â | Â | Â | 0.033 |
  Negative | 122 (75.3) | 37 (78.7) | 34 (87.2) | 19 (79.2) | 32 (61.5) |  |
  Positive | 40 (24.7) | 10 (21.3) | 5 (12.8) | 5 (20.8) | 20 (38.5) |  |
ATP synthase | Â | Â | Â | Â | Â | 0.610 |
  Negative | 2 (1.2) | 1 (2.1) | 1 (2.6) | 0 (0.0) | 0 (0.0) |  |
  Positive | 160 (98.8) | 46 (97.9) | 38 (97.4) | 24 (100.0) | 52 (100.0) |  |
SDHA | Â | Â | Â | Â | Â | 0.175 |
  Negative | 2 (1.2) | 2 (4.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |  |
  Positive | 160 (98.8) | 45 (95.7) | 39 (100.0) | 24 (100.0) | 52 (100.0) |  |
SDHB | Â | Â | Â | Â | Â | 0.006 |
  Negative | 52 (32.1) | 20 (42.6) | 16 (41.0) | 9 (37.5) | 7 (13.5) |  |
  Positive | 110 (67.9) | 27 (57.4) | 23 (59.0) | 15 (62.5) | 45 (86.5) |  |
PHGDH | Â | Â | Â | Â | Â | 0.027 |
  Negative | 61 (37.7) | 24 (51.1) | 11 (28.2) | 12 (50.0) | 14 (26.9) |  |
  Positive | 101 (62.3) | 23 (48.9) | 28 (71.8) | 12 (50.0) | 38 (73.1) |  |
PSPH | Â | Â | Â | Â | Â | 0.926 |
  Negative | 146 (90.1) | 42 (89.4) | 36 (92.3) | 22 (91.7) | 46 (88.5) |  |
  Positive | 16 (9.9) | 5 (10.6) | 3 (7.7) | 2 (8.3) | 6 (11.5) |  |
PSAT1 | Â | Â | Â | Â | Â | <0.001 |
  Negative | 140 (86.4) | 41 (87.2) | 37 (94.9) | 14 (58.3) | 48 (92.3) |  |
  Positive | 22 (13.6) | 6 (12.8) | 2 (5.1) | 10 (41.7) | 4 (7.7) |  |
SHMT1 | Â | Â | Â | Â | Â | 0.033 |
  Negative | 127 (78.4) | 43 (91.5) | 31 (79.5) | 18 (75.0) | 35 (67.3) |  |
  Positive | 35 (21.6) | 4 (8.5) | 8 (20.5) | 6 (25.0) | 17 (32.7) |  |
GLDC | Â | Â | Â | Â | Â | 0.547 |
  Negative | 96 (59.3) | 31 (66.0) | 24 (61.5) | 14 (58.3) | 27 (51.9) |  |
  Positive | 66 (40.7) | 16 (34.0) | 15 (38.5) | 10 (41.7) | 25 (48.1) |  |